Melanoma survivors face a care gap: major review maps what works and what is missing

Survival from melanoma has been transformed over the past decade. Checkpoint inhibitors and targeted BRAF/MEK inhibitors have pushed overall survival in advanced disease to levels that would have been unthinkable when metastatic melanoma was considered a death sentence. Yet a growing population of long-term survivors now lives with the lingering consequences of both the disease and the therapies that saved them, from fatigue, anxiety and depression to the practical challenges of returning to work and rebuilding social lives. A new scoping review published in the Journal of Cancer Survivorship has taken the most systematic look yet at how medicine is responding, and its findings reveal a field that is inventive but fragmented, with no single program covering everything survivors need.

The review, led by Madlen Hörold of the Institute of Social Medicine and Health Systems Research at Otto von Guericke University Magdeburg together with colleagues from Regensburg, Halle, Dresden and other German centers, followed the Joanna Briggs Institute methodology for scoping reviews and reported according to the PRISMA-ScR checklist. The team searched MEDLINE, the Cochrane Library, Web of Science and CINAHL for studies published between January 2015 and March 2026, using a search strategy built on the PCC framework of Population, Concept and Context. After an initial sweep that yielded 2,862 records and a second, extended search adding 1,189 more, the researchers screened titles and abstracts independently, resolved disagreements through discussion with a supervisor, and supplemented the database results with manual screening of reference lists. From 2,993 references, 21 studies made the final cut.

Those 21 studies, published between 2016 and 2026, comprised thirteen quantitative investigations, three qualitative studies, three reviews and two mixed-methods papers. Geographically, the literature is heavily skewed: nine studies came from Australia, four from the United Kingdom, and the remainder from Denmark, Poland, the Netherlands and Iran. That concentration is not accidental. Australia and New Zealand carry the world’s highest melanoma burden, with an age-standardized incidence of 37.0 per 100,000 in 2022, compared with 30.6 in Norway and 16.5 in the United States. Intriguingly, despite those high rates, the review identified no randomized controlled trials of survivorship care from Norway or the USA, a gap the authors highlight as unexpected.

Within the included literature, the researchers identified seven distinct survivorship care programs: ASICA, which stands for Achieving Integrated Self-directed Cancer Aftercare for Melanoma; Mel-Self, which incorporated the ASICA intervention; Melanoma Care; MELACARE; MELCARE; CAPABLE; and a regional pilot program in Poland’s Lower Silesian Voivodeship. To organize what these programs actually deliver, the team applied the Cancer Survivorship Care Quality Framework, a structure developed by Nekhlyudov and colleagues that distinguishes five clinical domains from several contextual ones. The analysis, conducted as a qualitative content analysis following the Elo and Kyngäs methodology with the software MAXQDA 22, mapped each program’s components onto prevention and surveillance for recurrences and new cancers; surveillance and management of physical effects; surveillance and management of psychosocial effects; surveillance and management of chronic medical conditions; and health promotion and disease prevention.

The most heavily populated domain was recurrence surveillance, addressed by twelve studies. Here the review drew on work by Silverstein and colleagues, who summarized National Comprehensive Cancer Network guidance recommending skin and lymph node examinations every three to six months for two years after treatment, then every three to twelve months for a further three years, and annually thereafter as clinically indicated. Several programs push this surveillance toward the patient and the primary care system. Kamminga and colleagues discussed low-threshold skin checks and shifting recurrence monitoring to general practitioners, while digital, tablet-based interventions described in multiple studies support total skin self-examination at home, with images and data routed to a dermatology nurse practitioner for timely clinical response. The ASICA trials in the UK exemplify this approach, pairing structured self-examination training with personalized skin maps and nurse feedback.

Physical effects of modern therapy received attention in nine studies, and this is where the immunotherapy era creates genuinely new clinical demands. Silverstein and colleagues described screening and management of acute and chronic immune-related adverse events, including cardiovascular disease, inflammatory conditions, endocrinopathy and lymphedema, stressing that any new signs or symptoms appearing after immune checkpoint inhibitor therapy must be appropriately investigated. Kamminga and colleagues, in their qualitative work with oncology providers, framed the need for uniform and patient-driven oncological follow-up as one of four core concepts of survivorship care, adaptable to individual patient circumstances. Chronic condition management, however, was the thinnest domain of all: only a single article addressed it, recommending routine follow-up visits plus bloodwork every six to twelve months to catch late immune-related effects such as endocrinopathies, and involvement of subspecialty care when chronic conditions emerge during treatment.

Psychosocial care fared considerably better, appearing in twelve of the twenty-one studies. Reported interventions ranged widely: screening for anxiety, depression, sleep disturbances and financial toxicity; assessment of fertility impact and social support systems; monitoring of melanoma-specific health-related quality of life; and education in coping with fear of cancer recurrence using metacognitive strategies such as detached mindfulness and worry postponement. The MELACARE trial in Denmark combined nurse-led follow-up with skin self-examination training and fear-of-recurrence management for early-stage patients. Telephone-based psychotherapeutic sessions appeared in the Melanoma Care program, while older trials reviewed within the literature tested spiritually focused meditation, which produced less depression and more positive affect among metastatic melanoma patients, and telephone-based peer support, which patients found an acceptable substitute for face-to-face contact. Kamminga’s team argued that psychosocial problems should at minimum be identified through short questionnaires or patient-reported outcome measures, including work-related difficulties that patients often hesitate to raise in clinic.

Beyond the five clinical domains, the review mapped contextual features of the healthcare system that determine whether programs actually function. Eighteen articles addressed communication and decision making, describing personalized information combined with practical guidance, referral guides clarifying where to seek help, short educational videos, a psychoeducational booklet titled Melanoma: Questions and Answers, and communication channels spanning phone, email, SMS and Skype. Clinical structure was another recurring theme, with nurse-led follow-up in person or by telephone, scheduled appointments with plastic surgeons, medical coordinators, and health information systems including electronic medical records and telehealth. Care coordination, emphasized in five articles, emerged as a critical ingredient: survivorship care plans to facilitate follow-up, multidisciplinary teams that reduce patient uncertainty by giving a clear overview of next steps, a fixed contact person or case manager such as a clinical nurse specialist, and fast-tracked unscheduled clinic visits when a tele-dermatologist recommends them.

The review’s verdict is nuanced. The literature collectively covers all main areas of the Cancer Survivorship Care Quality Framework, but no single program covers all domains, and most studies focused on patients with stage 0 to IIc disease, leaving survivors of advanced melanoma comparatively underrepresented. Pilot randomized trials showed their concepts were feasible and acceptable, and survivorship care appears to reduce anxiety and depression, potentially improving quality of life, but the programs demand substantial investment in human and technological resources. Two empirical gaps stand out sharply: health literacy, where only the MELCARE program offered guidance on self-management strategies and online resources, and health economics, where no included study provided cost analyses. The authors argue that with a plethora of health information available and digital health applications proliferating, promoting patients’ health literacy should be a high priority. Their findings are intended to feed directly into the participatory development of a multimodal, patient-centered survivorship care program for people living with and beyond melanoma, funded by German Cancer Aid, with further research needed to confirm the effectiveness of survivorship care plans and to establish their economic case before widespread implementation.

Subject of Research: Survivorship care programs and follow-up needs of melanoma patients

Article Title: Survivorship care for melanoma patients: a scoping review

Article References: Survivorship care for melanoma patients: a scoping review. (n.d.). https://doi.org/10.1007/s11764-026-02067-5

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02067-5

Keywords: melanoma, cancer survivorship, scoping review, immunotherapy, checkpoint inhibitors, skin self-examination, psychosocial care, health literacy, nurse-led follow-up, telehealth, recurrence surveillance, survivorship care plans